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REVIEW OF CURRENT LITERATURE ON THE DIAGNOSIS 
AND TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS 
SARAH V. BURLEY 
ABSTRACT 
This thesis reviews the current literature on idiopathic pulmonary fibrosis 
(IPF), a progressive, scarring lung condition largely affecting older adults that is 
experiencing an increasing incidence in the U.S. and abroad.  Two troubling 
clinical aspects of IPF are the difficulty of timely diagnosis and uncertain 
progression once diagnosed. The need for early detection is driven by the 
condition’s median survival rate post-diagnosis of about 3 years. Environmental 
and familial risk factors are important predictors of IPF, but cannot alone 
determine who is at risk for the condition.  High-resolution computed tomography 
is currently the best non-invasive diagnostic tool, but many efforts are now 
underway to identify biological markers, which may aid not only in diagnosis, but 
illuminate both susceptibility and progression of the disease.  Although the 
pathogenesis of IPF remains unclear, a compelling correlation has surfaced 
between the mechanics of IPF and herpes virus infection, which also may lead to 
a biological marker for the condition. Likewise, some genetic factors have shown 
promise in revealing pathogenesis and possible diagnosis. The only treatment 
currently available to ameliorate IPF is lung transplantation, but it is a last resort 
effort. In terms of pharmaceutical treatment, the most significant development 
has been the recent approval and use of two anti-fibrotic drugs, pirfenidone and 
		 vi	
nintedanib, that appear to slow the progression of the disease, but do not 
eliminate the fibrotic condition that impairs patients’ breathing. As efforts 
progress in addressing affirmative treatments for IPF, there is consensus that not 
enough is being done to address palliative and psychological needs of IPF.  In 
sum, a review of the current literature suggests tremendous accomplishments 
have made in treating what remains a fatal condition, but much work remains to 
truly understand how and why IPF occurs, and whether, short of lung 
transplantation, there are treatments that can improve, not just maintain, patients’ 
health.  
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INTRODUCTION 
 
 The goal of this thesis is to examine the current literature on Idiopathic 
Pulmonary Fibrosis (IPF) with regard to its diagnosis, treatment and effects in the 
context of prior views of the disease. While taking a holistic view of IPF, this 
thesis aims to highlight emerging diagnostic tools and newly-introduced 
treatments that provide earlier diagnosis and treatment, both fundamental in 
extending the lives of those with IPF. 
  IPF is a so-called “orphan” disease occurring in a small, but growing, 
population of older persons. It impairs lung function, often rapidly, resulting in 
death within several years of diagnosis, although the disease progresses 
differently depending on the patient.  Despite this, there have been recent efforts 
to provide more clinical certainty around the staging of the disease in order to aid 
in its treatment.   
 Long-held views that IPF was triggered by inflammation of uncertain origin 
have given way to agreement that alveolar micro-injuries resulting in excessive 
fibrotic growth is the mechanism at play in this condition.  Pharmaceutical 
treatments targeting this fibrotic growth have been recently introduced in an effort 
to delay progression, but currently only lung transplants have shown to be 
effective in improving patients’ lives (so much so, that patients with IPF are now 
the largest group of recipients of North American lung transplants).   
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 It has been suggested that there may be genetic or viral factors affecting 
individuals’ susceptibility to IPF, as well as related biomarkers that might be able 
to be used to aid in diagnosing the condition or managing its care.  However, for 
the present, IPF is best diagnosed through attention to distinctive auditory cues 
during auscultation and confirmed through radiological, spirometric, and/or 
histological examination.  Finally, there is a need for improved patient education 
regarding the treatment of IPF and its impact on them, as the current paucity of 
information may contribute to depression and resignation.  Nevertheless, 
prospects for patients with IPF are much better than they were as recently as ten 
years ago. 
	3 
PUBLISHED STUDIES 
 
Epidemiology of IPF 
            IPF is the most common type of idiopathic interstitial pneumonia (IIP)(Abe, 
2016).  It is a fatal condition of relatively short duration that tends to affect 
individuals over 65 years of age (Raghu, 2014).  The median duration of a 
patient’s life, once diagnosed with IPF, is approximately 3 years (Sampson, 
2015).  During 2014, IPF resulted in deaths estimated to number from 28,000 to 
65,000 in Europe and from 13,000 to 17,000 in the United States (Hutchinson, 
2014).  Incidence of the disease is reported to be akin to that of cancers of the 
stomach, liver, testes, and cervix (Hutchinson, 2015). IPF skews toward older, 
male patients (Kuwano 2016), who are also are reported as having a worse 
prognosis in some, but not all, studies of IPF (Raghu, 2011).  
IPF occurs worldwide with no predilection for ethnicity or race (Morrisey, 
2003).  Conservative estimates of incidence in North America and Europe are 
between 3 and 9 cases annually per 100,000 persons, based on a review of 
published studies since 2000 (Hutchinson, 2015).  Mortality rates of IPF continue 
to increase steadily worldwide (Hutchinson, 2014).  Presumably, this can in part 
be attributed to wider familiarity with the condition (and thus its diagnosis) and 
greater consensus on the mechanics of such diagnosis. Another factor that is 
likely contributing is simply the fact that people are living longer now than ever 
before, and this disease is one that presents in an older population.  However, 
the incidence and prevalence of IPF varies globally, which is likely attributable to 
local differences in diagnosing the condition, as well as the sample size, methods 
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and statistics used in the studies from which such conclusions are drawn 
(Nalysnyk, 2012). 
            Nonetheless, the upward trend in IPF globally over time is evident in the 
literature.  For example, in a review of a large health insurance claims database 
in the U.S. over the period 1996-2000, annual incidence was reported as 6.8 per 
100,000 applying a comparatively narrow IPF diagnostic standard, and 16.3 per 
100,000 under a broader test, while prevalence was 14.0 per 100,000 under the 
stringent standard and 42.7 per 100,000 under the broader criterion (Raghu, 
2006).  In a more recent review of patient files between 2006–2012 in the 
HealthCore Integrated Research Database -- employing a newly-developed 
screening algorithm for U.S. adults (limited in application to patients older than 50 
years of age) -- produced an estimated incidence (for the population, not just the 
50+ cohort) of 14.6 per 100,000, while prevalence was 58.7 per 100,000 
(Esposito, 2015). In Europe, estimated annual incidence/prevalence per 100,000 
was 0.22/1.25 in Belgium, 0.93/3.38 in Greece, 0.94/6.5-12.1 in the Czech 
Republic, 2.17/NA in Denmark, 3.0/NA in Spain, 4.3/23.4 in Norway, and 7.94/NA 
in the United Kingdom (Kuwano, 2016).  In Japan, one study determined 
incidence/prevalence is 2.23/10.0 per 100,000 (Kuwano, 2016). 
            As the name indicates, IPF is of uncertain etiology but is thought to be 
associated with a variety of risk factors, including occupation, cigarette smoking 
and viral infections (Baumgartner, 2000).  Exposure to inhalation agents remains 
the most common aggregate risk factor, with prolonged, repetitive injury to the 
lungs potentially contributing to the fibrotic processes (Kuwano, 2016). IPF has 
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also been observed to occur in a familial pattern (affecting two or more members 
of an immediate family), although the occurrence of such familial cases varies in 
studies between 2% and 25% of all IPF cases (Tang, 2003).  However, one study 
concluded that among all risk factors associated with IPF, having a parent or 
sibling with IPF was the highest single risk factor (odds risk (OR) = 6.1)(Garcia-
Sancho, 2011). 
Outside of the environmental and genetic factors noted above, there are 
several medical conditions that tend to present alongside IPF. A literature review 
that considered 126 studies from 1990 to 2015, determined significant 
comorbidities associated with IPF. The respiratory comorbidities were as follows: 
pulmonary hypertension (34%), chronic obstructive pulmonary disease (18%), 
lung cancer (15%), obstructive sleep apnea (6%), and pulmonary embolism (2%). 
The non-respiratory comorbidities included cardiovascular disease (27%), 
metabolic disease (24%), and gastro-esophageal reflux disease (18%) (Raghu, 
2015). The nature of these associations, whether they are causal or share 
common risk factors (e.g., age), has not been determined.  
Gastroesophageal reflux (GER) is often associated with IPF, suggesting 
that these patients have an enhanced risk of aspiration of oropharyngeal or 
gastric contents into the larynx and lower respiratory tract and that recurrent 
aspiration contributes in some way to lung injury (Lee, 2010). What makes it 
even more mysterious is that one study of comorbidities associated with IPF 
found that GER represented enhanced survival rates (Kreuter, 2016).  The 2015 
clinical guidance issued by the ATS/ERS/JRS/ALAT Committee on Treatment of 
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IPF suggests that clinicians use regular anti-acid treatment for patients with IPF, 
but notes that the committee has very low confidence in estimates of effect 
(Raghu, Rochwerg 2015).  Despite the cautious position, use of anti-acid 
treatment in IPF cases has been found to be associated with lowered instances 
of fibrosis as well as longer survival and smaller decreases in FVC (Daccord, 
2016). Nevertheless, there has been no confirmation that GER plays a causative 
role in IPF, indicating that further study is needed to review the efficacy of anti-
acid treatment (Daccord 2016).  
             
Current Knowledge of Pathology 
IPF is characterized by the distortion of lung structure and resulting loss of 
respiratory function (Konigshoff, 2008).  It is a chronic progressive condition 
associated with initial injury to alveolar epithelial cells followed by abnormal 
repair (Kuwano, 2016).  The abnormal repair is characterized by increased 
fibroblastic proliferation and extracellular matrix remodeling (Morrisey, 2003). The 
proliferative fibrotic response results in hyperplastic, hypertrophic, and 
metaplastic epithelium, cystic honeycomb change, septal expansion, and 
variable inflammation (Meuten, 2012). The distorted lung architecture, associated 
with alveolar epithelial cell injury and myofibroblast activation (Konigshoff, 2008), 
and the loss of gas exchanging surface area produce the symptoms patients 
experience associated with IPF (e.g., breathlessness, decreased exercise 
tolerance). 
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            It should be noted that, in general, fibrosis represents the innate and 
adaptive immune response to pathogen (Thannickal, 2014).  Both fibroblasts and 
myofibroblasts participate in host defense by containing pathogens to either 
eliminate them or prevent their spread (Thannickal, 2014).  However, other types 
of lung inflammation and injury can also lead to fibrosis, such as that caused 
by allergens, chemicals, radiation and environmental particulates (Coultas, 
1994).    
            For a long time, the etiology of IPF was presumed to involve inflammation 
of the lungs.  According to a 2001 literature review of studies published between 
1965 and 2000, the then-prevailing hypothesis was that the fibrosis associated 
with IPF resulted from a chronic inflammatory process preceding the disease, in 
turn injuring the lung and triggering lung fibrogenesis that produced the end-
stage fibrotic scar (Selman, 2001).  This hypothesis was disproved through the 
review, which found no empirical evidence that inflammation was the triggering 
factor in the onset of the condition.  Conversely, the review demonstrated that 
epithelial injury in the absence of inflammation could still stimulate fibrosis 
(Selman, 2001).  Rather than inflammation, the literature review identified an 
emerging view that IPF involves “abnormal wound healing in response to multiple, 
microscopic sites of ongoing alveolar epithelial injury and activation associated 
with the formation of patchy fibroblast-myofibroblast foci, which evolve to fibrosis” 
(Selman, 2001).  A separate study in 2001 reached the same conclusion, finding 
that “the critical pathway to end-stage fibrosis is not ‘alveolitis’ but rather the 
ongoing epithelial damage and repair process associated with persistent 
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fibroblastic proliferation. Controlling these processes, rather than stopping 
inflammation, appears most important in preventing progressive disease and the 
fatal outcome common in IPF” (King, 2001). This remains the prevailing view 
today (Kuwano, 2016). 
            As noted above, fibrosis typically constitutes a response to 
infection.  However, the same cellular and molecular mechanisms in humans that 
are genetically programmed to produce defensive fibrotic responses to infectious 
pathogens may have been co-opted to respond to noninfectious stressors in our 
modern environment (Thannickal, 2014).  In other words, our immune system 
has not had sufficient evolutionary time to allow it to discriminate effectively 
between the hostile and the non-hostile (Thannickal, 2014).  Meta-analysis of 
several IPF studies has indicated a wide range of risk factors associated with 
environmental and occupational influences: Smoking (OR)=1.58); 
Agricultural/Farming (OR=1.65); Livestock (OR=2.17); Wood Dust (OR=1.94); 
Metal Dust (OR=2.44); and Stone/Sand (OR=1.97) (Kuwano, 2016).  In short, 
chronic, repeated exposure to both industrial and rural inhalants may represent 
triggers for micro-injuries that some individuals’ lungs simply are unprepared to 
deal with, leading to an uncontrolled and inappropriate fibrotic response. 
             As the scientific community strives to define the pathology of IPF, an 
interesting relationship between herpesviruses and the occurrence of IPF has 
been observed and is being considered as a potential contributing factor of 
disease progression. This association was best demonstrated by a 2003 study 
that found the DNA of Epstein-Barr virus (EBV), cytomegalovirus (CMV), or 
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human herpesviruses (HHV-7 or HHV-8) were present in lung tissues of 97% of 
patients with IPF, compared with 36% of control patients (Tang, 2003).  In 
addition, two or more herpesviruses (CMV, EBV, and HHV-8) were identified in 
57% of patients with IPF compared to 8% of controls (Tang, 2003).  
            Further evidence in favor of a contributory role for such infections in IPF 
comes from a study of gammaherpesvirus-68. In this study, the virus appeared to 
exacerbate already-existing pulmonary fibrosis through the up-regulation of 
chemokines, followed by recruitment of pulmonary fibrocytes and in turn fibrosis 
(McMillan, 2008). This effect may be more pronounced depending on patient 
age.  In a subsequent study, young and old populations of mice were infected 
with gammaherpesvirus-68.  Compared to respective controls, the older 
populations, but not the younger, experienced significant increases in collagen 
content and fibrosis (Naik, 2011).  Enzyme-linked immunosorbent assay (ELISA) 
testing showed a higher level of transforming growth factor-β in whole lung 
homogenates from the infected aged mice (Naik, 2011).  Another study 
suggested possible therapeutic or prophylactic measures for IPF, in that 
depletion of CD8+ T-cells during the course of murine herpesvirus infection 
served to prevent the development of fibrotic lung disease in such mice. The 
study suggests that viral matrix M1-induced CD8+ T-cells are mediators of 
fibrotic disease-inducing inflammation and altered cellular recruitment to the lung 
results in immunopathology and fibrosis (O’Flaherty, 2015).  It has been 
concluded, based on both human post-mortem and in vivo murine studies that 
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herpesvirus infection may “act as a second hit that precipitates or worsens lung 
fibrosis” (Kropski, 2012).  
            Despite the evidence of exacerbation, it remains unclear whether such 
viruses serve to contribute to the initial occurrence of IPF, or are merely an 
example of opportunistic infection following the onset of IPF (Kuwano 
2016).  However, recent research supports those advocating a causative 
role.  The DNA of Herpesvirus saimiri (endemic but non-pathogenic in squirrel 
monkeys) was found in the regenerating epithelial cells of 21 of 21 IPF cases, 
with none found in the 21 control subjects. Reverse transcription polymerase 
chain reaction testing demonstrated that that the source of the cyclin D RNA in 
active IPF was Herpesvirus saimiri and not human (Folcik, 2014).  This suggests 
an etiological role for Herpesvirus saimiri in human IPF and is consistent with the 
studies of murine gammaherpes-68, which is closely related to Herpesvirus 
saimiri (Folcik, 2014).  
            As the data showed that IPF, and no other types of pulmonary fibrosis, is 
associated with Herpesvirus saimiri, it has been suggested that this particular 
virus may prove to be a valuable diagnostic tool to identify IPF among patients 
with unspecified pulmonary fibrosis (Folcik, 2014).  In other words, the strength of 
the association with the virus (100% effective in the study) means that despite 
doubt over the causative sequences, the presence of such viral evidence offers 
clinicians a potentially powerful tool to rule IPF in, or out, in suspected cases of 
IPF. Though the exact relationship between the two has yet to be confirmed, the 
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above research suggests a strong linkage between the mechanics of IPF and 
herpesvirus infection that demands further study. 
  
Diagnosis of IPF 
Symptoms 
 Typically, the first indication that a person has IPF is the gradual onset of 
shortness of breath (dyspnea) upon exertion. In light of the tendency of the 
condition to present in older patients, this could be initially attributed to aging in 
general or to other medical conditions such as emphysema, heart disease or a 
respiratory tract infection. Because of the symptom overlap, diagnosis of IPF can 
be delayed several months after its symptomatic onset (Loveman, 2015).  Other 
symptoms of IPF include a non-productive (dry) cough, reduced exercise 
tolerance and increased anxiety, while less frequent symptoms may include 
fatigue, depression and chest pain (Loveman, 2015).  One study suggests that 
there may also be cognitive aspects of IPF presented to clinicians:  applying a 
battery of tests to a control group and to patients with either severe or mild IPF, it 
found that those with more severe IPF demonstrated worse cognitive function 
than the other subjects (Bors, 2015).  This confirmed, without referencing it, a 
2009 published report (to date uncited in the IPF literature) that found that 
patients with IPF appeared to have a cognitive function deficit on a test that 
requires sustained visual attention (Sprunger, 2009).  Both reports suggested the 
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need for additional studies to explain the differences and to tailor treatments to 
address them. 
International Standards 
 Diagnosis of IPF has proven challenging for clinicians, as its symptoms 
are so often similar to those of other conditions (see below).  In 2002, the 
American Thoracic Society (ATS)/European Respiratory Society (ERS) 
advocated a multi-disciplinary approach for diagnosing all instances of IIP, 
including IPF, calling for diagnostic interaction among clinicians, radiologists, and 
pathologists (Abe, 2016).  In 2011, ATS and ERS issued revised the definition of 
IPF and provided further diagnostic guidance with the Japanese Respiratory 
Society and the Latin American Thoracic Association (Abe, 2016).   
 Under the current 2011 standard, IPF is defined as a “specific form of 
chronic, progressive fibrosing interstitial pneumonia of unknown cause, occurring 
primarily in older adults, limited to the lungs, and associated with the 
histopathologic and/or radiologic pattern of [Usual Interstitial Pneumonia (UIP)].” 
(Raghu, 2011).  These standards provide that a diagnosis of IPF may only be 
made with the following (Raghu, 2011): 
Table 1 - 2011 International Standards for Diagnosis of Idiopathic Pulmonary Fibrosis 
• Exclusion of other known causes of interstitial lung disease (ILD) (e.g., domestic and 
occupational environmental exposures, connective tissue disease, and drug toxicity). 
• The presence of a UIP pattern on high-resolution computed tomography (HRCT) in 
patients not subjected to surgical lung biopsy. 
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• Specific combinations of HRCT and surgical lung biopsy pattern in patients subjected to 
surgical lung biopsy.  
 
Clinical Examination 
 While much of the research today centers around identifying biomarkers of 
IPF, the initial presentation of IPF is most likely to be detected though routine 
examination.  This is because upon clinical examination, more than 90% of those 
experiencing IPF will exhibit inspiratory crackles (described as “Velcro®-like 
crackles”) typically heard at the lung bases posteriorly (Behr, 2012).  Crackles 
may be a good early indicator of IPF(Oldham, 2014).  A French academic 
practitioner argues that, for patients over 60, the presence of crackles that persist 
after several deep breaths in successive examinations conducted several weeks’ 
apart should strongly raise a suspicion of IPF and be followed by diagnostic 
HRCT to confirm (Cottin, 2012).   In addition to crackles that can be identified 
easily in the clinical setting, up to 50% of patients with IPF will display finger 
clubbing, although this tends to be associated with more advanced disease 
(Oldham, 2014). 
HRCT 
 As reflected by the international diagnostic standards, HRCT plays a vital 
role in the identification of IPF in those patients suspected of having the condition.  
A 2005 international study considered the efficacy of use of HRCT by 
community-based physicians and found (based on blind review by a panel of 
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three independent radiologists in the study) that two reviewers reached 
consensus that confirmed the prior physician’s HRCT-based diagnosis of IPF in 
81.3% of cases (Lynch, 2005).  The most prevalent physiological condition 
evident in the HRCT and observed by reviewers in confirming the earlier 
diagnosis of disease was honeycombing (Lynch, 2005). 
Biopsy 
 In view of its comparatively intrusive nature, subjecting patients to a lung 
biopsy has long been viewed as appropriate only where clinical and/or 
radiological examination in diagnosing IPF is uncertain or otherwise inconclusive 
(Hunninghake, 2001).  A study of all patients who underwent surgical lung 
biopsies in connection with possible interstitial lung diseases between 2000 and 
2011 found that the in-hospital mortality rate following such biopsies was 6.4% 
(Hutchinson, Fogarty, 2015).  However, the efficacy of surgical lung biopsies may 
justify the risk. A 1999 study concluded that among newly-diagnosed patients 
with IPF, the diagnosis would have been missed in one-third of patients had a 
biopsy for histological review not been performed (Raghu, 1999). Whether 
technological advancements in HRCT since 1999 might obviate the need for 
biopsies is unclear, but worthy of study.  
 A new, less invasive method of biopsy has been shown to be effective in 
yielding sufficient lung tissue samples for examination for IPF (Tomassetti, 2016).  
Bronchoscopic lung cryobiopsy involves the use of compressed gas delivered by 
a cryoprobe to chill lung parenchyma, allowing a tissue sample to be collected 
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(Patel, 2016).  Provided that the same level of histological information is available, 
in a recent one-center study, this technique yielded diagnostic results 
comparable to that of surgical lung biopsy (Tomassetti, 2016).  However, a 
recent editorial notes that this study is of limited utility because it does not 
consider accuracy but rather consensus of findings, because it involves only one 
site, and because of a lack of demonstration of the safety and yield of 
bronchoscopic lung cyrobiopsies (Patel, 2016).  Of particular concern, one-third 
of patients undergoing bronchoscopic lung cyrobiopsies suffered pneumothorax 
 (Patel, 2016). Nevertheless, in view of the substantial probative value that lung 
biopsies can bring to the diagnosis of IPF, and the potentially lower morbidity 
relative to surgical lung biopsies, there are sound reasons for expanding 
consideration of this new technique to augment existing surgical biopsy options. 
 The histopathologic features of IPF seen on lung biopsy include a 
heterogeneity with patchy areas of interstitial inflammation, fibroblast foci, and 
honeycombing interspersed among areas of normal lung. Fibroblast foci (FF) are 
small aggregates of proliferating myofibroblasts and fibroblasts (Raghu, 2011).  A 
2001 retrospective study of 87 biopsy-diagnosed patients with IPF employed four 
pathologists to assess the presence of various histological patterns relative to the 
patients’ survival.  It found that the extent of FF alone was predictive of mortality 
(King, 2001).  Conversely, the observed degree of alveolar space cellularity, 
alveolar wall fibrosis, and cellularity were found to be unrelated to mortality. A 
2002 retrospective study of 53 patients subjected to biopsies considered the 
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presence of four histological features (FF, interstitial mononuclear cell infiltrate, 
established fibrosis, and intra-alveolar macrophages). It found the strongest 
correlation between an increasing extent of FF and mortality (Nicholson, 2002).   
Lung Capacity (FVC) 
 It has been observed that a measured decline in forced vital capacity 
(FVC) is consistent with disease progression while also being predictive of 
reduced survival time (Richeldi, 2014).  A retrospective study reviewed FVC 
results within one month of HRCT-based diagnosis and again as recorded at 6 
months (±3 months) following diagnosis. Patients were placed in one of three 
groups based on relative change in FVC percent over the study period:  stable 
(decline <5%), marginal decline (decline ≥5% but <10%), or significant decline 
(decline ≥10%) (Reichmann, 2015).  The study showed the more FVC declined in 
the first 6 months after the initial IPF diagnosis, the worse the clinical outcome 
and the likelihood of increased IPF-related health resources utilization. The 
study’s author argues that the incremental burden of the decline in FVC on 
patients and the healthcare system illustrates the importance of physicians’ 
seeking to preserve lung function in patients with IPF (Reichmann, 2015). This 
suggests aggressive use of the pharmaceutical anti-fibrotics, as discussed below.  
Moreover, as illustrated below, FVC, and change in FVC, have both been 
employed in a comprehensive model of IPF progression. 
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Diagnostic and Treatment Biomarkers 
 While research continues on IPF pathogenesis and treatment, IPF survival 
rates remain largely unchanged, demonstrating the urgent need for identifying 
biomarkers associated with IPF (Fernandez, 2012).  Biomarkers can play several 
roles: screening for susceptibility to IPF; diagnosing IPF; evaluating progression 
of IDF, including the potential for acute exacerbation (discussed below).  Efforts 
to apply genetic testing to early IPF detection are underway, but have not yet 
produced results.  However, genome linkage analysis has identified a variant on 
the short arm of chromosome 11 in the promoter region of the mucin 5b gene is 
strongly associated with IPF (Putman, 2014).  However, the search for potential 
markers remains in the early stages (Ley, 2014).  NIH researchers, working 
under the “Precision Medicine” initiative, have identified a number of ongoing 
clinical trials that may result in the development of IPF biomarkers (Brownell, 
2016) 
 Serological biomarkers would be preferred as they do not require patient 
effort, are reproducible and are less invasive than pulmonary function testing or 
bronchoalveolar lavage (Chiba, 2016).  There are prospects for broader use of 
biomarkers, such as surfactant protein-A, surfactant protein-D and glycoprotein 
Krebs von den Lungen-6 (KL-6) for managing IPF (Chiba, 2016). KL-6 may prove 
to be a significant tool for predicting the progression of IPF when tested at initial 
diagnosis.  A 2006 retrospective study among Japanese patients found that, 
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when measured against a benchmark of 1000 units/ml, those patients with initial 
KL-6 levels below this threshold experienced a median survival greater than 36 
months, while those with KL-6 levels above had a median survival of only 18 
months (Yokoyama, 2006).  In a later study on German patients, a benchmark of 
1300 units/ml was applied to account for genetic differences between Japanese 
and Caucasian subjects.  It confirmed that baseline serum KL-6 level is a 
sensitive predictor for the onset of “acute exacerbation” of IPF (see below) for 
this population (Ohshimo, 2014). 
 As noted above, the presence of Herpesvirus saimiri correlates strongly to 
IPF and not to other types of pulmonary fibrosis.  Thus, DNA testing for 
Herpesvirus saimiri in particular (as contrasted with other related viruses) may 
also prove to be an important diagnostic biomarker (Folcik, 2014).  
 There may be other viable prospects for serum-based testing.  One study 
has found that patients with IPF testing positively via Western Blot or ELISA for 
heat shock protein 70 (HSP70) IgG autoantibodies in the serum are more likely 
to experience near-term lung function deterioration and mortality (Kahloon, 2013).  
This suggests both the possibility of effective testing for the presence of such 
autoantibodies in serum to predict the progression of previously-diagnosed 
disease while also illustrating that IPF progression may be linked with antigen-
specific autoimmunity. If humoral autoimmunity has a pathogenic role in IPF 
progression, then effective treatment could be developed to target these 
autoantibodies (Kahloon, 2013).  Another study considering HSP70 suggests that 
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genetic variation in observed in certain HSP70-related genes, as determined by 
serum testing, may influence the likelihood of developing IPF (at least in the 
study’s Mexican population) (Aquino-Galvez, 2015). 
 Elevated levels of Immunoglobulin A (IgA) in patients with IPF correlate 
with greater risk of mortality from the disease (ten Klooster, van Moorsel, 2015).  
IgA production is regulated by transforming growth factor (TGF)-β, a cytokine that 
is associated with the development of pulmonary fibrosis. While TGF-β is up-
regulated in patients with IPF, it is reported to be difficult to use as a 
biomarker.  Instead, it may prove possible to use serum IgA as a proxy (Ten 
Klooster, van Moorsel, 2015). 
 Another potential biomarker related to TGF-β is the presence of certain 
microRNAs in patients with IPF’ blood serum. MicroRNAs (miRNAs) are small 
RNA molecules involved in tissue development and differentiation, cellular 
proliferation, and tissue repair (Yang, 2015).  A key study determined that nearly 
10% of the miRNAs found in the lungs of patients with IPF had experienced 
significant changes.  Many of these implicated miRNAs are regulated by 
transforming growth factor β1 (TGF-β1) (one of the TGF-β family), but also 
regulate the TGF-β1 pathway. Aberrant expression of miRNA results in a release 
of inhibitions affecting the TGF-β1 pathway and to the creation of feed-forward 
loops (Pandit, 2011).  Studies have identified microRNAs that alter proliferative 
and migratory properties of fibroblasts, and induce phenotypic changes in 
epithelial cells (Pandit 2015). It has been suggested that imbalance between 
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profibrotic miRNAs and antifibrotic miRNAs may be closely associated to IPF 
progression (Rho, 2015).  By shifting focus from presence of miRNAs in the 
lungs to those in serum, a study in China evaluated a relative small sample of 
patients and found that a significant number of serum miRNA molecules were 
altered in patients with IPF, raising the prospect that differentially expressed 
miRNAs in serum may play a role in the disease’s progression (Yang, 2015).  
 To summarize, the following table identifies the prospective biomarkers 
and their respective roles relative to IPF: 
Table 2 - Possible Biomarkers for IPF  
 
Genetic 
Chromosome 11 Mucin 5b (diagnosis) 
 
Serological 
Surfactant protein-A (diagnosis) 
Surfactant protein-D (diagnosis) 
KL-6 (acute exacerbation)  
Herpesvirus saimiri (diagnosis) 
HSP70 (acute exacerbation and possible susceptibility) 
IgA (mortality) 
MicroRNA (mortality) 
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Progression of the Disease 
 Extensive heterogeneity has been observed among individual patients 
with IPF, with the disease’s clinical course proving difficult to anticipate with 
confidence (Hambly, 2015).  The 2011 international standards indicate that the 
natural history of IPF is variable and unpredictable, with most patients 
experiencing “a gradual worsening of lung function over years” (Raghu, 2011).  In 
some cases, patients experience significant functional impairment and death 
within months of diagnosis (Hambly, 2015).  Others may encounter a sudden 
decline (termed “acute exacerbation”) only after an otherwise long period of 
previous stability (Raghu, 2011).  Acute exacerbation is associated with a 
mortality rate as high as 85% and mean survival periods of between 3 to 13 days 
(Juarez, 2015).  
 This varying set of responses to the disease mean that normal 
approaches to fibrotic diseases – assigning risk based on clinically observed 
variables (i.e., history and physical examination, pulmonary function, exercise 
testing, radiographic findings, and histological examination) – are “poorly 
reflective of disease pathogenesis and provide insufficient power to accurately 
predict clinical outcome” (Hambly, 2015).  Difficulty in anticipating the course of 
IPF necessarily complicates the clinical determination of how best to treat the 
disease. 
 For years, there was no standardized test to distinguish among mild, 
moderate, and severe instances of IPF, although those conducting clinical trials 
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generally employed two different lung physiology variables to establish a 
segmenting test to differentiate between mild-to-moderate patients from those 
with severe IPF:  a FVC threshold of 50–55% predicted and a diffusing capacity 
of carbon monoxide (DLCO) threshold of 35–40% (Kolb, 2014).  An early 
longitudinal model based on seven factors (dyspnea, chest radiograph, 
spirometry, lung volume, diffusion capacity, resting alveolar-arterial Po2, and 
exercise O2 saturation) resulted in a clinical, radiological and physiological (CRP) 
scoring system that predicted, with some confidence, survival IPF rates based on 
observations over a six-month period  (Watters, 1986).  However, given the 
imprecision of IPF diagnosis at that time, the value of these conclusions today is 
unclear. 
 In 2012 a streamlined model of disease staging was developed using only 
four baseline variables:  gender, age and the two lung physiology factors noted 
above (FVC and DLCO).  This approach, termed “GAP” (Gender/Age/Physiology), 
resulted in both a three-stage scoring system, which provides as a quick 
screening tool for use in the clinical setting, as well as a more specialized risk 
calculator for calibrating treatment in previously-diagnosed patients (Ley, 2012).  
Its discriminatory power was validated in studies in Korea (although the 3-year 
mortality projection could not be confirmed) (Kim, 2015).  However, over a 2-year 
period, patients’ GAP stage was not associated with differences in yearly lung 
function decline in an international study involving over 600 patients (Salisbury, 
2016).  These predictive failings of GAP may be addressed by a new model, 
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Longitudinal GAP, which, like the CRP score, takes account of changes over 
time (in this instance, the patient’s history of respiratory hospitalization and 24-
week change in FVC (Ley, 2015).  Given its novelty, there are no studies on the 
discriminatory and predictive powers of the Longitudinal GAP model, but 
presumably there are ongoing studies testing it. 
 
Treatment of IPF 
 IPF remains a major cause of illness and mortality and thus reflects a 
largely unmet medical need (Spagnolo, 2015).  However, over the past five years, 
new pharmaceutical treatments have made significant strides to ameliorate the 
impact of IPF on patients.  Despite these advances, it should be noted that 
surgical intervention through lung transplantation (LTx) remains the sole therapy 
that can effectively remove the cause of IPF related dyspnea (but this treatment 
is a last resort).  
Pharmaceutical Treatment 
 Because inflammation was long thought to be associated with the 
development of IPF, glucocorticoids or immunosuppressive agents represented 
the conventional approach to the treatment of patients, especially those with 
milder cases of the disease (Bando, 2016).  However, the 2011 
ATS/ERS/JRS/ALAT guidance recommended that IPF not be treated with 
corticosteroid monotherapy, cyclosporine A therapy, or the combination of 
corticosteroid with immunosuppressant (azathioprine or cyclophosphamide) 
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(Bando, 2016).  Underlying the emergence of this new thinking was a 2012 study 
that found that a triple anti-inflammatory treatment regime using N-acetyl 
cysteine, prednisone, and azathioprine was, in fact, significantly harmful to 
patients with IPF.  The trial was abandoned when it was found to have resulted in 
a 10% increase in mortality – largely due to respiratory causes – and a material 
(>300%) increase in hospitalization and adverse effects (Raghu, 2012). 
 Rather than immunosuppressant agents, since October, 2014, mild-to-
moderate IPF is now treated with either of two recently FDA-approved oral 
antifibrotics: pirfenidone and nintedanib.  However, their efficacy in severe IPF 
and the optimal length of therapy remain unknown, given their relatively recent 
introduction. Neither has yet been recommended in international IPF guidelines 
(Handa, 2016).    
 Pirfenidone, a pyridone, is believed to act via anti-inflammatory and 
antifibrotic chemical pathways, although its exact mechanism is unknown 
(Karimi-Shah, 2016).  It is thought to attenuate TGF-β production and effect 
(Fernandez, 2012). Meta-analysis of three European/Japanese trials of 
pirfenidone showed a reduction the proportion of patients experiencing a greater 
than 10% predicted decline in FVC in nearly 44% in the pirfenidone group 
compared with placebo (Noble, 2016). Similarly, An FDA-mandated study prior to 
U.S. approval found a relative reduction of 50% in the proportion of patients who 
had such a decline in predicted FVC (Aravena, 2015). It has been observed that 
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pirfenidone in trials produced more favorable mortality rates than did nintedanib, 
but this may be due to differently structured trials (Wells, 2016).	
  Nintedanib is a tyrosine kinase inhibitor first used to treat IPF in Japan.  It 
has been shown to have a broad inhibitory activity on the downstream signaling 
cascades of fibroblasts and myofibroblasts (Wollin, 2015). Nintedanib was found 
to reduce the decline in FVC while also delaying the onset of acute exacerbation  
(Richeldi, 2014).  The number of deaths in the nintedanib group was consistent 
those in the placebo group, but the study may not have been powered to 
demonstrate a mortality benefit. 
 It must be noted these newly-introduced oral therapies (pirfenidone and 
nintedanib) do not reverse the fibrosis; they merely delay patients’ functional 
decline (O’Flaherty, 2015).  Moreover, one recent study has concluded that using 
both drugs in combination, rather than either alone, demonstrates greater 
efficacy in reducing in vitro proliferation of fibroblastic cells (Lehtonen, 2016). 
This was presaged by a 2015 editorial that succinctly noted that “[c]ombination 
therapy is the IPF treatment of the future (Wells, 2015). The challenge in 
structuring combined or successive uses of different treatments, according to Drs. 
Kolb, Jenkins and Richeldi, is that with “IPF, we still do not know how to define 
treatment failure. The decline of lung function over a definite period of time...has 
been widely used to assess disease progression and risk of death in IPF, but its 
value has been questioned…and it does not necessarily reflect the effect of 
therapy on an individual and hence can't define treatment failure.” (Kolb, 2016).  
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They argue that more controlled studies, not merely retrospective data reviews, 
on the combined use of both drugs must be pursued in an effort to balance 
“individual needs with community sustainability”. (Kolb, 2016).  
According to clinicaltrials.gov, a number of potential therapies are under 
investigation, including antiviral therapy targeting herpesvirus. As noted above, a 
potential linkage between herpesvirus and IPF has been identified (Kropski, 
2012). 
Oxygen Therapy and Ventilation 
 Unsurprisingly, given the universal dyspnea suffered by patients with IPF, 
ambulatory oxygen therapy is often used in the treatment of patients with 
hypoxemia due to IPF.  Despite the passage of time, as of 2013, no clinical trials 
have evaluated the functional outcomes or survival of patients with IPF based on 
either short or long-term oxygen therapy (Criner, 2013).  A Mayo Clinic 
retrospective statistical study of patients in the mid-1990s concluded that patients 
with IPF treated with oxygen fared worse than those not receiving this treatment 
(Douglas, 2000). This study could not, however, determine whether the use of 
oxygen therapy correlated with severity of disease or in fact reflected a lower 
incidence of survival resulting from the oxygen therapy (Douglas, 2000).  
 Similarly, a 2005 review of HRCT use found, without further comment, that 
the supplemental use of oxygen was a significant risk factor for mortality of 
patients with IPF (Lynch, 2005).  Despite the lack of clinical trials and the results 
of the reviews linking use and mortality, most physicians treating patients with 
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IPF reportedly believe that supplemental oxygen treatment is appropriate for use 
when resting, exercise, or  nocturnal peripheral oxygen saturation falls below 
89% (Holland, 2014).  “This belief is likely driven by clinicians’ unwillingness to 
leave uncorrected something…that can be remedied when so many other 
aspects of the disease are untreatable.” (Holland, 2014).  Thus, oxygen therapy 
remains a key palliative component in the management of patients with IPF, as it 
appears to improve symptoms and overall quality of life (Criner, 2015).   
 Mechanical ventilation is sometimes used for patients with IPF suffering 
acute exacerbation resulting in hospitalization.  Acute exacerbation affects a 
significant minority of patients with IPF, but is associated with high mortality.  A 
comprehensive review of medical records of over 17,000 patients with IPF 
between 2006 and 2012 considered the comparative use of mechanically 
invasive ventilation (MV) (endotracheal or tracheostomy tube) and noninvasive 
mechanical ventilation (NIMV).  The overall mortality for the entire cohort of 
patients with IPF was 11.3%.  MV patients experienced higher mortality (51.6% 
vs. 30.9%), were younger (66.3 years vs. 70.2 years), and had longer hospital 
stays (13.3 days vs. 6.5 days) than those receiving NIMV (Rush, 2016).  Perhaps 
confirming the benign impact of patients’ use of ambulatory oxygen therapy, such 
use by those in the study had no impact on the mortality between the MV and 
NIMV cohorts (Rush, 2016).  It must be noted that the severity of condition that 
likely prompted the use of MV over NIMV in the first instance makes comparisons 
between the impact of these modalities of care difficult. 
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Pulmonary Rehabilitation 
 Many studies have found a benefit from pulmonary rehabilitation, although 
there is no accepted standard on the type, intensity or duration of such treatment 
(Puglisi, 2016). In a review of such studies, pulmonary rehabilitation was found, 
perhaps unsurprisingly, to result in “improvement in exercise tolerance, 
particularly a transient increase in the distance travelled in the walk test or a 
decrease in heart rate”. (Puglisi, 2016).   
 Yet, there is doubt regarding the long-term benefit of such treatment.  For 
example, a 2015 report found that in comparing patients with IPF in Israel who 
underwent a 12-week course of pulmonary rehabilitation with a control group that 
did not, the findings with respect to survival and cardio-respiratory-related 
hospitalizations showed no significant differences (Vainshelboim, 2015). In a 
sense, then, pulmonary rehabilitation may be viewed akin to palliative care – 
allowing improvements in quality of life (or end of life) without delivering 
improvements in arresting or reversing the underlying condition.  However, there 
can be no doubt that patients with IPF are in acute need of improvement of their 
psychological and emotional conditions.  
Lung Transplant 
 As a general rule, patients with IPF qualify for LTx when post-transplant 
life expectancy exceeds their current life expectancy without the transplant 
(George, 2015). Because of the severity of the disease and the efficacy of the 
treatment, IPF is currently the most common indication for which United Network 
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for Organ Sharing allocates lungs for transplant, having increased from 15% in 
2000 to 37% in 2009 (George, 2015).  In addition to the narrow classes of 
absolute surgical contraindications, the following relative contraindications have 
been observed for IPF (George, 2015): 
Table 3 - Relative Contraindications for Lung Transplant Procedure for Treatment of IPF 
 
• Recipient older than 65 years. 
• Unstable clinical condition (e.g., shock or ventilator dependence). 
• Limited functional status with poor rehabilitation potential. 
• Body mass index (calculated as weight in kilograms divided by height in meters squared) 
of greater than 30 
 
 In view of challenges in predicting the relative mortality of patients with IPF, 
current LTx waiting list guidelines recommend early referral of all patients with 
histologic or radiographic evidence of IPF in the following order (George, 2015): 
Table 4- Lung Transplant Waiting List Criteria for Interstitial Lung Diseases 
• Histologic or radiographic evidence of [UIP] and 1 or more of the following: [DLCO] of less 
than 39% predicted; decrease in [FVC] by 10% during a 6-month period; decrease in 
pulse oximetry to less than 88% during [6 minute walking distance (6MWD)]; and 
pulmonary fibrosis score of greater than 2 on computed tomography. 
• Histologic evidence of nonspecific interstitial pneumonia and 1 or more of the following: 
[DLCO] of less than 35% predicted; decrease in [FVC] by 10% during a 6-month period; 
and decrease in [DLCO] of 15% during a 6-month period. 
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Interestingly, the factor having the most predictive value of mortality of those on a 
waiting list is lower 6MWD score.  It was strongly and independently associated 
with an increased mortality rate for wait-listed patients with IPF, and was a better 
predictor of death at six months on the waiting list than was FVC predicted 
(Lederer, 2006).  In particular, patients who cannot walk more than 207 meters in 
six minutes have a high mortality rate in the absence of LTx (Lederer, 2006). 
 Many patients with IPF receiving a LTx can be expected to survive for 
years beyond the procedure.  Recently, the results of a retrospective study on all 
Dutch patients with IPF who were registered for LTx between 1989 and 2001 
were released.  Of these 98 patients, 30% died waiting for a LTx, while 52 
patients received a LTx with a median survival post-surgery of 10 years.  Of 
those who died on the waiting list, 21.9% were deemed high-urgency based on 
the prevailing European transplant standards, while 38.6% were elective patients 
(ten Klooster, Nossent, 2015).  In the end stage of IPF in older patients, bilateral 
lung transplantation (BLT) is the preferred course to single lung transplantation, 
as it has a significantly improved survival rate (Gulack, 2015). Nevertheless, in 
the Dutch study, those patients with IPF slated for BLT appear to have an 
increased risk of pre-transplant mortality (ten Klooster, Nossent, 2015).  
Presumably, they were judged, rightly, as having a more acute need for LTx than 
others on the list, although the higher mortality may simply be attributable to 
relative scarcity of double lungs for transplant. 
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Palliative 
  As compared with patients with cancers, palliative care and hospice are 
typically much less used by those with other types of chronic lung diseases 
(Gilbert, 2009).  For example, in a study of 277 deceased patients with IPF seen 
in a Pittsburgh hospital between 2000 and 2012 whose location of death could be 
determined, 57% died in the hospital, with only 13.7% receiving a formal 
palliative care referral, with nearly a quarter of those receiving such referral within 
1 month of their death (Lindell, 2015). One recent article summed up the 
situation: “Despite the recognized need, efforts to provide effective palliation 
often fall short for patients and families living with chronic respiratory 
disease….The situation is even worse for patients living and dying with 
pulmonary fibrosis, who have received scant attention until recently.” (Rocker, 
2015).   
Psychological 
 With a condition with a prognosis as uniformly grim as IPF, and in light of 
the frequent delay in its diagnosis from the outset of symptoms, and the 
uncertainty over the progression of the disease in individual patients, it seems 
reasonable to expect many patients with IPF to struggle emotionally and 
psychologically with their diagnosis.  A qualitative survey of a group of 17 
patients in England between 2007 and 2012 confirmed that patients reported 
“struggling to get a diagnosis and coping with a life-limiting, rapidly progressive 
illness with no good treatment and few support structures” (Duck, 2015).  It 
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should be noted that during the pertinent period, neither pirfenidone nor 
nintedanib was yet available.  During the European trials for pirfenidone, a similar 
qualitative survey was undertaken of 71 patients with IPF receiving the drug.  
They also reported similar difficulties with diagnosis and the impact of the 
condition on their quality of life (Russell, 2016).  However, they also related that 
pirfenidone had given them a measure of hope despite concerns over side 
effects (nausea and photosensitivity), but those using supplemental oxygen 
reported less hope, mainly because its use limited their activities and identified 
them publicly as other than healthy (Russell, 2016). 
 An Internet-based survey using the Patient-Reported Outcomes 
Measurement Information System® (PROMIS®) conducted twice with 220 
patients with IPF during an undisclosed period of time (thus making consideration 
of the impact of pharmaceutical treatments impossible) found that depression 
scores of patients with IPF were comparable to those seen in individuals with 
major depressive disorders (Yount, 2016).  This study also found that those 
receiving supplemental oxygen therapy were more impaired than non-users in 
fatigue, physical function, and social role participation (Yount, 2016).  
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DISCUSSION 
 
 It is axiomatic that the resources, both intellectual and financial, to 
research all medical conditions is limited.  Yet surprisingly, the phrase “managed 
research” appears in resources indexed by Web of Science only 20 times, while 
“managed care” is employed 15,117 times.  This begs the question:  how does 
our society prioritize efforts to deepen our understanding of medical conditions 
such as IPF?  This is not a new problem.  In 2003, a seminal report asserted that 
“systematic flaws exist in the production of scientific evidence, in part because 
there is no consistent effort to conduct clinical trials designed to meet the needs 
of decision makers. (Tunis, 2003).   
 As seen above, there is currently a wide range of IPF-related research 
underway, some to validate the efficacy of the newly-introduced pharmaceutical 
treatments, others to explore the potential genetic underpinnings of IPF, while 
more seek biomarkers to aid in quicker and more effective diagnosis relative to 
scanning or biopsies.  To which efforts should priority be given? In some sense 
there is an acute need to understand whether pirfenidone and nintedanib (alone 
or together) have the prospect of doing more than just delaying death, if only to 
validate the projected cost of nearly $100,000 annually being spent on such 
drugs for each American IPF patient taking them (Morrow, 2015).   
 Yet, as we consider the issue more broadly, there are strong arguments 
for focusing efforts around the goal of identifying strongly predictive biomarkers 
for IPF.  This is especially the case if such biomarkers do more than merely 
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diagnose the condition but give clinicians the ability to tailor their care for patients. 
Considering such personalized medicine efforts more generally, it has been 
argued that “[i]f successfully implemented, these biomarker diagnostics would 
potentially save the health care system billions of dollars and prevent needless 
patient burden due to futile interventions.” (Hey, 2015).  Thus, it could be argued 
that more focus should be placed on intensifying the search for IPF diagnostic 
and treatment biomarkers – especially to identify earlier in life those susceptible 
to IPF – with a view to delaying or avoiding the onset of the disease. In addition, 
with the emergence of effective pharmaceutical treatment, biomarkers might be 
able to provide insight in terms of when and how to utilize nintedanib and/or 
pirfenidone. It is an exciting possibility that perhaps certain biomarkers could 
enhance personalized treatment, in that their presence or absence could indicate 
which patients with IPF are more likely to respond to nintedanib or pirfenidone, or 
neither. This information would be invaluable in terms of slowing disease 
progression.  
 But, paradoxically, even with such biomarkers, science today lacks 
confidence in determining what triggers IPF, so even with a means of identifying 
an at-risk set of individuals, there is no targeted means of eliminating risk factors.  
All that can be offered is advice to shun particulates and cigarette smoke that are 
thought to be associated with the micro injuries to the lungs that are associated 
with IPF.  However, as noted above, familial occurrence of IPF has been found to 
be a stronger associated factor than environmental conditions. This suggests 
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more research is needed to explore this apparent strong genetic element (or the 
need for new research to better control for environmental co-factors). Thus, until 
there is a better understanding of the mechanism by which the cellular damage is 
triggered, it makes more sense to focus on biomarkers that confirm the presence 
of IPF.  Improved confidence in diagnosis – without having to resort to biopsies 
and HRCT – would reduce costs and save months of delay seen today in 
confirming the condition. Work on specifying the mechanics of cell injury and 
prophylactic measures to protect at-risk persons should be pursued, and the 
cost-benefit of pirfenidone and nintedanib use must be validated.  Because LTx 
is currently so relied upon as a last resort treatment for advanced IPF, efforts to 
examine how to improve the results of such treatment for IPF and all other 
conditions are needed. For example, chronic lung allograft dysfunction, 
specifically bronchiolitis obliterans, affects “50% of [all lung transplant] patients 
within 5 years after the transplant procedure and [causes] up to 30% of late 
mortality between 3 and 5 years after transplantation” (Verleden, 2014).  Finally,, 
in a development that may expand the hopes of patients with IPF needing LTx, it 
has been suggested recently that single LTx, rather than double LTx, is as 
effective and should be pursued in order to make donor lungs more widely 
available to patients with IPF (Chauhan, 2016).. 
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CONCLUSION AND SUGGESTIONS FOR FURTHER RESEARCH 
 
Great strides have been made in the diagnosis and treatment of IPF in the 21st 
Century.  However, despite this progress, it remains a fatal disease. The 
literature suggests the following areas as opportunities for further research to 
broaden the understanding of the disease, its risk factors, progression and 
treatment: 
• Etiology: Given the wide variety of reported incidence of familial cases of 
IPF, and the growing evidence of genetic factors related to susceptibility, a 
more concentrated effort to examine the true risk of familial IPF is needed. 
• Etiology: In view of the international variation in reported incidence and 
prevalence, it would be helpful to better understand whether there are 
variations in the populations or in diagnostic measures that are driving this 
observed variation. 
• Etiology: Given the evidence of a potential viral nexus, further efforts are 
needed to explore the contribution of Herpesvirus saimiri and other viral 
agents  
• Impact: Further examination of cognitive impairment reported in one study 
should be undertaken. 
• Diagnostic: Are surgical biopsies still necessary to effectively diagnose 
IPF, or is the less-invasive cryoprobe alternative sufficient? 
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• Diagnostic: Serum-based biomarkers are needed to diagnose IPF, monitor 
response to treatment, and aid in predicting it prognosis. Thus, this should 
be a primary focus of research activity. 
• Diagnostic: In light of the familiarity of the GAP elements, steps should be 
taken to validate the efficacy of Longitudinal GAP in predicting the 
disease’s progression. 
• Diagnostic: A better understanding of the predictive and diagnostic power 
of the 6MWD test is needed as it relates to progression and mortality. 
• Treatment: Broader studies of pirfenidone and nintedanib over a longer 
period of time should be undertaken, with particular attention to combined 
usage and the potential improvement in effect. 
• Treatment: The optimal role of ambulatory oxygen therapy and pulmonary 
rehabilitation should be better characterized in patients with IPF. 
• Treatment: Seek efforts to improve survival of all LTx recipients, IPF and 
otherwise 
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